ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,210,445 | -17.4% | 222,100 | +1.7% | 0.00% | 0.0% |
| Q2 2023 | $1,464,793 | -23.2% | 218,300 | +1.1% | 0.00% | 0.0% |
| Q1 2023 | $1,907,280 | +3.4% | 216,000 | -10.6% | 0.00% | 0.0% |
| Q4 2022 | $1,845,060 | +9.8% | 241,500 | +2.3% | 0.00% | 0.0% |
| Q3 2022 | $1,681,000 | -11.0% | 236,100 | +1.1% | 0.00% | 0.0% |
| Q2 2022 | $1,889,000 | -37.3% | 233,500 | +7.7% | 0.00% | -50.0% |
| Q1 2022 | $3,011,000 | -46.8% | 216,900 | +7.6% | 0.00% | -33.3% |
| Q4 2021 | $5,657,000 | -17.4% | 201,600 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $6,852,000 | -15.9% | 201,600 | +1.1% | 0.00% | -20.0% |
| Q2 2021 | $8,152,000 | -0.3% | 199,500 | -1.8% | 0.01% | 0.0% |
| Q1 2021 | $8,177,000 | -30.7% | 203,100 | +1.8% | 0.01% | -37.5% |
| Q4 2020 | $11,802,000 | +40.6% | 199,600 | +15.6% | 0.01% | +14.3% |
| Q3 2020 | $8,394,000 | +2.5% | 172,600 | +2.0% | 0.01% | 0.0% |
| Q2 2020 | $8,186,000 | – | 169,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |